

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stephen P. MASSIA *et al.*

Serial No.: 10/716,293

Filed: November 17, 2003

For: THERAPEUTIC BIOCONJUGATES

Group Art Unit: 1654

Examiner: Niebauer, Ronald T.

Atty. Dkt. No.: AZTE:015US

Confirmation No.: 8809

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below.

November 19, 2007

Date

Mark B. Wilson

AMENDMENT AND RESPONSE TO OFFICE COMMUNICATION DATED OCTOBER 17, 2007, REGARDING NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

Commissioner:

This paper is submitted in response to the Office Communication dated October 17, 2007, setting forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, for which the date for response is November 19, 2007 (November 17, 2007 falls on a Saturday).

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/AZTE:015US.

An Amendment to the specification begins on page 3 of this paper.

A Response begins on page 5 of this paper.

Reconsideration of the application in view of the amendments and remarks contained herein is respectfully requested.